Bridgewater Resources, LLC
Letter data
- Company
- Bridgewater Resources, LLC
- Recipient
- Robert W. Runkle, Betty R. Runkle | Owners | Bridgewater Resources, LLC | Bridgewater Resources, LLC | 334 Main Street | Liberty | , | TX | 77575 | United States
- Issue date
- 2018-12-06
- Posted date
- Not available
- FDA office
- Office of Human and Animal Food Operations West Division 3
- Subject
- Not available
- Product
- Not available
- CMS ID
- 541081
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Bridgewater Resources, LLC
MARCS-CMS 541081 —
December 06, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
UPS Overnight
Recipient:
Recipient Name
Robert W. Runkle, Betty R. Runkle
Recipient Title
Owners
Bridgewater Resources, LLC
Bridgewater Resources, LLC
334 Main Street
Liberty
,
TX
77575
United States
Issuing Office:
Office of Human and Animal Food Operations West Division 3
4040 N. Central Expressway
Suite 300
Dallas
,
TX
75204
United States
Dear Mr., and Mrs. Robert Runkle:
The Food and Drug Administration has completed an evaluation of your firm’s corrective actions in response to our Warning Letter (case 541081, dated March 9, 2018). Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Jessica E. Hensley
Director, Compliance Branch
Human & Animal Food Operations, WD3
Content current as of:
12/18/2018